<DOC>
	<DOC>NCT01131078</DOC>
	<brief_summary>A study of Avastin (bevacizumab) in combination chemotherapy in patients with metastatic cancer of the colon or rectum. The anticipated time on study treatment is until disease progression.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>adult patients &gt;=18 years of age; colon or rectal cancer, with metastases; &gt;=1 measurable lesion. previous systemic treatment for advanced disease; radiotherapy to any site within 4 weeks before study; daily aspirin (&gt;325 mg/day), anticoagulants, or other medications known to predispose to gastrointestinal ulceration; coexisting malignancies or malignancies diagnosed within last 5 years (except basal cell cancer or cervical cancer in situ).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>